J Montero, A Manzano et al., with wide experience on development of new tools and therapies for personalized cancer treatment, have generated a new technology that enables testing multiple anticancer treatments for precision medicine in less than 24 hours. Furthermore, they are developing a new benchtop instrument to perform these analyses in situ in an inexpensive and accessible manner.<\/p>\n
The group is looking for partners and investors, but other collaborations may be considered.<\/p>\n
Cancer patients are treated following therapeutic regimens based on pathologic and molecular information (mostly genomic). However, tumors rapidly adapt leading to resistance and relapse and certain patients do not benefit from therapies selected based on this strategy. Alternatively, functional assays directly expose patient\u2019s tumor cells to potential therapeutic agents to determine which will be the best treatment for each patient<\/u>.<\/p>\nDescription<\/h3>\n
The technology consists of a novel functional assay that rapidly measures drug-induced apoptotic induction and enables testing multiple anticancer treatments directly on alive patient-isolated cancer cells in less than 24 hours for precision medicine.<\/p>\n
The RTA assay uses an apoptotic catalyser to accelerate this cell death process by days. By comparing RTA profiles of non-treated and shortly incubated cells with anticancer drugs, it can predict days in advance if a given agent will sensitize cells towards apoptosis, which indicates future treatment cytotoxicity and clinical efficacy. Moreover, RTA keeps the cells alive and it is compatible with other analyses (omics).<\/p>\n
The Real-time Tracking of Apoptosis (RTA) assay, together with a microfluidic device and a LED-based readout method will enable the implementation of precision medicine to identify the best treatment for each patient<\/u>.<\/p>\n The team has already generated preliminary results using different tumor models and primary samples treated with multiple anticancer treatments. Three RTA versions are now developed using flow cytometry, high-throughput microscopy and microfluidics, depending on specific sample requirements and agents tested.<\/p>\n","protected":false},"excerpt":{"rendered":" Executive summary J Montero, A Manzano et al., with wide experience on development of new tools and therapies for personalized…<\/p>\n","protected":false},"author":2,"featured_media":17398,"parent":1399,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-tecnologies.php","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-19762","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/19762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=19762"}],"version-history":[{"count":2,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/19762\/revisions"}],"predecessor-version":[{"id":19765,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/19762\/revisions\/19765"}],"up":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/1399"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media\/17398"}],"wp:attachment":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=19762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Current stage of development<\/strong><\/h3>\n